Clinical Trial Search

Primary: Period 1: Percent Absolute Bioavailability (%F) for TAK-935 — 12.57 percent absolute bioavailability

Primary: Number of Participants With Any Treatment-emergent Adverse Event (TEAE) — 7; 7; 81; 7 Participants

Primary: Number of Participants With Adverse Events (AEs) — 7; 11; 3; 7 Participants

Primary: Number of Participants With Dose Limiting Toxicities (DLTs) and Maximum Tolerated Dose (MTD) — 0; 0; 0; 1 Participants

Primary: Change in Metabolic Clearance of D6-25(OH)D3 — 21; 5 ml/d

Primary: Plasma Pamiparib Pharmacokinetics: Area Under the Concentration-time Curve (AUC) From Time Zero to Infinity (AUC0-∞) — 29300 hours*nanograms/milliLiter (h*ng/mL)

Primary: Number of Participants With Solicited Local Reactogenicity Events — 11; 3; 17; 1 Participants

Primary: Maximum Tolerated Dose (MTD) of DDFPe Evaluated by Number of Dose Limiting Toxicities — 0; 0; 0; 0 Dose Limiting Toxicities

Primary: Frequency of Occurrence of Neutropenia ≥ Grade 3 — 0; 0; 0; 0 Participants

Primary: Change in Pain Units on a Scale (0-10) 0 Being Least, 10 Being Worst Pain From Baseline — 2.00 pain units on a scale — p=<0.001

Primary: Pharmacokinetics: Area Under the Concentration Time Curve (AUC) of LY2140023 and LY404039 — 1420; 1360; 836; 926 nanograms*hours per milliliter (ng*h/mL)

Primary: Pharmacokinetics: Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC[0-inf]) of LY2140023 and LY404039 in Treatment Period 1 — 1160; 2620…

Primary: Antibody Titer (Serum Anti-Aβ1-42 Free IgG) - Mean Absolute Value — 632.3; 335.4; 162.8; 751.5 AU/mL (AU: Arbitrary Unit)

Primary: Pharmacokinetics: Maximum Observed Plasma Concentration (Cmax) of LY2140023 — 251; 171 nanograms per milliliter (ng/mL)

Primary: Pharmacokinetics: Maximum Concentration (Cmax) of LY2140023 — 277; 290; 304; 284 nanograms per milliliter (ng/mL)